Aberrant EGFR signaling drives non‐small cell lung cancer (NSCLC) development, and despite the success of tyrosine kinase inhibitor (TKI) therapies in treating NSCLC, TKI resistance remains a major obstacle. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.